Our News
Alnylam Leaders at BIO International Convention 2020/"Digital BIO"
June 7, 2020
Alnylam Pharmaceuticals
Even though the BIO International Convention has gone virtual for 2020 as a result of COVID-19, Alnylam leaders will continue to contribute to the informative, lively and always timely discourse that characterizes this annual biopharma event regarded by many as the "Superbowl" of the industry. This year, BIO Digital Week will consist of a mix of live and on-demand sessions. Convention registrants can hear from Alnylam leaders in the following sessions.
Alnylam's Anant Murthy, Sharon Labreche and Alan EisenbergLive Panel Sessions:
"How will healthcare systems adapt to the Post-COVID-19 World?" (Monday, June 8th 9:00-9:55 AM PDT) featuring Alan Eisenberg, Alnylam's Vice President, Global Government Relations and Public Policy.
Panel Description - Thanks to the incredible biomedical innovation taking place today, COVID-19 will hopefully soon be a thing of the past. However, the strain on resources due to the pandemic will be felt by healthcare systems across the globe for years to come. How will countries respond to this new reality to ensure patients maintain access to the latest biotech innovations? This panel will focus on the impact of COVID-19 on healthcare systems and how countries can better respond to the post-pandemic constraints on healthcare systems.
Learn more about this panel session here.
"Diversity and Inclusion in Biotech’s Explosion: ERG and Non-Profit Perspectives" (Wednesday, June 10th 4:20-5:25 PM PDT) featuring Sharon Labreche, Alnylam's Vice President of Global Talent Acquisition.
Panel Description - Biotech is increasingly embracing the fact that as an innovation industry delivering tomorrow's medicines, it derives huge value from an incredibly vibrant talent base among immigrants, people of color, LGBTQ people and an array of other minority groups.
Panelists represent diversity and inclusion (D&I) managers or ERG representatives from a spectrum of companies investing heavily in representational workforces as well as the industry's largest LGBTQ non-profit. They will share their perspectives on how the industry's appreciation for D&I is changing, and give practical advice for developing D&I policies and corporate cultures that acknowledge and raise up diverse perspectives to the enrichment of all.
Learn more about this panel session here.
On-Demand Panel Sessions:
"Start Me Up: How Can Europe’s Biotech Sector Combat the Coronavirus?" featuring Alnylam's Anant Murthy, Vice President Pricing, Market Access & Policy, Europa/Canada/MEA; General Manager, Canada, BENELUX, Nordics and Portugal.
Panel Description - The role of the biotechnology sector in addressing global challenges has become clear during the current pandemic. Nearly 75% of COVID-19 R&D for treatments, vaccines and diagnostics programs are undertaken by small companies. How has the European biotech sector contributed to the COVID-19 response? Are small to medium-sized European biotechnology companies equipped to enter the race to find treatments and vaccines? This panel will focus on the current state of the European biotech sector and its preparedness to respond to the pandemic. Panelists will discuss the lessons learned from the COVID-19 crisis and the policies and strategy needed to support the life sciences sector moving forward.
Registered BIO International Convention attendees can access the on-demand replay here.
"In an Era of Partisan Stalemate, What Drug Pricing Policies Can the Executive Branch Enact Without Congressional Authority?" featuring Alan Eisenberg, Alnylam's Vice President, Global Government Relations and Public Policy.
Panel Description - Congress and the White House have seemed at odds on many positions but united in at least one – drug prices are too high. Candidates vying for the presidency have made it a top campaign issue.
In an era when disagreement within Congress results in reduced legislation, what policies can the president enact through executive action alone? And if the office changes hands in 2020, what shifts in drug pricing policy can we expect to see? This panel, featuring perspectives by a former FDA official, former congressional staffer and drug manufacturer, will take a deep dive into executive authority on health care policy, discuss what is and is not possible and consider how things could change after the 2020 election.
Registered BIO International Convention attendees can access the on-demand replay here.
FOLLOW US
